Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2
Ovarian cancer (OC) is the leading cause of death among women with gynecologic malignancy. Breast Cancer Susceptibility Gene 1 (BRCA 1) and Breast Cancer Susceptibility Gene 2 (BRCA 2) germline mutations confer an estimated 20 to 40 times increased risk of OC when compared to the general population....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/3/172 |
| _version_ | 1797472061479714816 |
|---|---|
| author | Lauren Clarfield Laura Diamond Michelle Jacobson |
| author_facet | Lauren Clarfield Laura Diamond Michelle Jacobson |
| author_sort | Lauren Clarfield |
| collection | DOAJ |
| description | Ovarian cancer (OC) is the leading cause of death among women with gynecologic malignancy. Breast Cancer Susceptibility Gene 1 (BRCA 1) and Breast Cancer Susceptibility Gene 2 (BRCA 2) germline mutations confer an estimated 20 to 40 times increased risk of OC when compared to the general population. The majority of BRCA-associated OC is identified in the late stage, and no effective screening method has been proven to reduce mortality. Several pharmacologic and surgical options exist for risk-reduction of gynecologic malignancy in BRCA 1/2 mutation carriers. This review summarizes up-to-date research on pharmacologic risk-reducing interventions, including the oral contraceptive pill, acetylsalicylic acid/nonsteroidal anti inflammatory drugs (ASA/NSAID) therapy, and denosumab, and surgical risk-reducing interventions, including risk-reducing bilateral salpingo-oophorectomy, salpingectomy with delayed oophorectomy, and hysterectomy at the time of risk-reducing bilateral salpingo-oophorectomy. |
| first_indexed | 2024-03-09T19:56:55Z |
| format | Article |
| id | doaj.art-5b1642abb9de4540a74aafc523686e7f |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T19:56:55Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-5b1642abb9de4540a74aafc523686e7f2023-11-24T00:53:32ZengMDPI AGCurrent Oncology1198-00521718-77292022-03-012932132214010.3390/curroncol29030172Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2Lauren Clarfield0Laura Diamond1Michelle Jacobson2Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaTemerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaDepartment of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1E2, CanadaOvarian cancer (OC) is the leading cause of death among women with gynecologic malignancy. Breast Cancer Susceptibility Gene 1 (BRCA 1) and Breast Cancer Susceptibility Gene 2 (BRCA 2) germline mutations confer an estimated 20 to 40 times increased risk of OC when compared to the general population. The majority of BRCA-associated OC is identified in the late stage, and no effective screening method has been proven to reduce mortality. Several pharmacologic and surgical options exist for risk-reduction of gynecologic malignancy in BRCA 1/2 mutation carriers. This review summarizes up-to-date research on pharmacologic risk-reducing interventions, including the oral contraceptive pill, acetylsalicylic acid/nonsteroidal anti inflammatory drugs (ASA/NSAID) therapy, and denosumab, and surgical risk-reducing interventions, including risk-reducing bilateral salpingo-oophorectomy, salpingectomy with delayed oophorectomy, and hysterectomy at the time of risk-reducing bilateral salpingo-oophorectomy.https://www.mdpi.com/1718-7729/29/3/172ovarian neoplasmsgenesBRCA 2genesBRCA 1endometrial neoplasms |
| spellingShingle | Lauren Clarfield Laura Diamond Michelle Jacobson Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2 Current Oncology ovarian neoplasms genes BRCA 2 genes BRCA 1 endometrial neoplasms |
| title | Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2 |
| title_full | Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2 |
| title_fullStr | Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2 |
| title_full_unstemmed | Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2 |
| title_short | Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2 |
| title_sort | risk reducing options for high grade serous gynecologic malignancy in brca1 2 |
| topic | ovarian neoplasms genes BRCA 2 genes BRCA 1 endometrial neoplasms |
| url | https://www.mdpi.com/1718-7729/29/3/172 |
| work_keys_str_mv | AT laurenclarfield riskreducingoptionsforhighgradeserousgynecologicmalignancyinbrca12 AT lauradiamond riskreducingoptionsforhighgradeserousgynecologicmalignancyinbrca12 AT michellejacobson riskreducingoptionsforhighgradeserousgynecologicmalignancyinbrca12 |